Donafenib combined with transarterial chemoembolization(TACE)and camrelizumab as conversion therapy for initial unresectable hepatocellular carcinoma(HCC):a prospective,single-arm,single center,phase Ⅱ clinical study

CAO Yajuan; ZHANG Xuebin; SHI Jiong; TANG Min; CHENG Chunxiao; YU Decai

doi:10.3969/j.issn.1009-0460.2023.06.001

Home>Articles>Donafenib combined with transarterial chemoembolization(TACE)and camrelizumab as conversion therapy for initial unresectable hepatocellular carcinoma(HCC):a prospective,single-arm,single center,phase Ⅱ clinical study

DOI: 10.3969/j.issn.1009-0460.2023.06.001

Donafenib combined with transarterial chemoembolization(TACE)and camrelizumab as conversion therapy for initial unresectable hepatocellular carcinoma(HCC):a prospective,single-arm,single center,phase Ⅱ clinical study

CAO Yajuan

ZHANG Xuebin

SHI Jiong

TANG Min

CHENG Chunxiao

YU Decai

Keywords：Hepatocellular carcinoma(HCC)Transarterial chemoembolization(TACE)DonafenibCamrelizumabConversion therapy

Publication Date：2023-06-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：7( 481-487 )

Chinese Clinical Oncology

ISTIC

ISSN：1009-0460

Year, Vol.(Issue)：2023,28(6)